Chinese Multi-provincial Cohort Study-Beijing Project (CMCS-Beijing)

December 2, 2020 updated by: Beijing Institute of Heart, Lung and Blood Vessel Diseases
The Chinese Multi-provincial Cohort Study (CMCS)-Beijing project is a sub-study in CMCS participants from Beijing, which intended to investigate the progression and determinants of atherosclerosis and aging related health problems through repeat examinations. Exam 0 to Exam 3 have been conducted during 1992 to 2012. Exam 4 is scheduled in 2020.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

3000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
      • Beijing, China
        • Peking University Shougang Hospital
      • Beijing, China
        • Beijing Sijiqing Hospital, Beijing
      • Beijing, China
        • Peking University Hospital, Beijing

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 100 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Study participants were recruited from the Chinese Multi-provincial Cohort Study-Beijing Project

Description

Inclusion Criteria:

  • Participants from CMCS-Beijing
  • sign the informed consent

Exclusion Criteria:

  • participanting in clinical trials

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All fatal and nonfatal acute coronary and stroke events
Time Frame: From date of enrollment until the date of first documented event or date of cardiovascular death, whichever came first, assessed at least 5 years
Acute coronary heart disease events included acute myocardial infarction, sudden death, and other coronary deaths. Acute stroke events included subarachnoid hemorrhage, intracerebral hemorrhage, or cerebral infarction.
From date of enrollment until the date of first documented event or date of cardiovascular death, whichever came first, assessed at least 5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
New-onset of coronary events
Time Frame: From date of enrollment until the date of first documented event or date of CHD death, whichever came first, assessed at least 5 years
Acute coronary heart disease events included acute myocardial infarction, sudden death, and other coronary deaths.
From date of enrollment until the date of first documented event or date of CHD death, whichever came first, assessed at least 5 years
New-onset of stroke
Time Frame: From date of enrollment until the date of first documented event or date of stroke death, whichever came first, assessed at least 5 years
Acute stroke events included subarachnoid hemorrhage, intracerebral hemorrhage, or cerebral infarction.
From date of enrollment until the date of first documented event or date of stroke death, whichever came first, assessed at least 5 years
Total death
Time Frame: From date of enrollment until date of death from all cause, assessed at least 5 years
All cause death
From date of enrollment until date of death from all cause, assessed at least 5 years
Cognitive dysfunction
Time Frame: From date of enrollment until date of first documented event, assessed at least 5 years
Cognitive dysfunction
From date of enrollment until date of first documented event, assessed at least 5 years
Olfactory Disorders
Time Frame: From date of enrollment until date of first documented event, assessed at least 5 years
Olfactory Disorders
From date of enrollment until date of first documented event, assessed at least 5 years
Valvular disease
Time Frame: From date of enrollment until the date of first documented event or date of valvular disease death, whichever came first, assessed at least 5 years
Valvular disease
From date of enrollment until the date of first documented event or date of valvular disease death, whichever came first, assessed at least 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Beijing Institute of Heart, Lung and Blood Vessel Diseases

Investigators

  • Principal Investigator: Jing Liu, MD, PhD, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 7, 2020

Primary Completion (ANTICIPATED)

March 1, 2021

Study Completion (ANTICIPATED)

March 1, 2021

Study Registration Dates

First Submitted

January 22, 2020

First Submitted That Met QC Criteria

January 31, 2020

First Posted (ACTUAL)

February 5, 2020

Study Record Updates

Last Update Posted (ACTUAL)

December 4, 2020

Last Update Submitted That Met QC Criteria

December 2, 2020

Last Verified

December 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CMCS-Beijing 2020

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on Cardiovascular risk factors

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe